Key result
Clopidogrel hyporesponsiveness linked to ~5-fold higher risk of MI, stent thrombosis, and death.
Answers are grounded in this paper and cite their sources.
This review highlights the clinical impact of aspirin and clopidogrel hyporesponsiveness in coronary stenting and discusses the role of platelet function testing, genetic screening, and newer P2Y12 inhibitors (prasugrel, ticagrelor) in personalizing antiplatelet therapy.
Patients undergoing coronary artery stenting receive an antiplatelet regimen to reduce the risk of antithrombotic complications. Current guidelines recommend the use of acetyl salicylic acid (aspirin) and clopidogrel as evidenced by large clinical trials. There has been a concern about variable responses of patients to aspirin and clopidogrel which may predispose them to subacute stent thrombosis or late stent thrombosis. Up to 25% of patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) were found to have hyporesponsiveness or resistance to clopidogrel which may predispose them to recurrent events. Dual antiplatelet regimen is a standard therapy in these patients and there is always a concern about variable responses to aspirin and clopidogrel predisposing them to acute coronary syndrome (ACS). Prevalence of this hyporesponsiveness or resistance may be due to noncompliance, genetic mutations, co-morbid situations and concomitant use of other drugs. This issue is of considerable importance in the era of coronary drug eluting stents when a long-term dual antiplatelet regimen is needed. This paper is a review for clinicians taking care of such patients with hyporesponsiveness or nonresponsiveness to dual antiplatelet regimen.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2009) conducted a review in Coronary artery stenting (PCI). Dual antiplatelet therapy (aspirin and clopidogrel) was evaluated on Subacute or late stent thrombosis and recurrent ischemic events. Up to 25% of acute myocardial infarction patients undergoing PCI have clopidogrel hyporesponsiveness, and nonresponders face a 5-fold increased risk of MI, stent thrombosis, and death.
Synapse has enriched 10 related papers. Consider them for comparative context: